[go: up one dir, main page]

PA8493701A1 - Compuestos para tratar la obesidad - Google Patents

Compuestos para tratar la obesidad

Info

Publication number
PA8493701A1
PA8493701A1 PA84937A PA8493701A PA8493701A1 PA 8493701 A1 PA8493701 A1 PA 8493701A1 PA 84937 A PA84937 A PA 84937A PA 8493701 A PA8493701 A PA 8493701A PA 8493701 A1 PA8493701 A1 PA 8493701A1
Authority
PA
Panama
Prior art keywords
compounds
treat obesity
npy
npy antagonists
antagonists
Prior art date
Application number
PA84937A
Other languages
English (en)
Inventor
Richard Louis Elliot
Marlys Hammond
Richard Frederick Hank
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8493701A1 publication Critical patent/PA8493701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ANTAGONISTAS DE NPY, PROCEDIMIENTOS PARA USAR TALES ANTAGONISTAS DE NPY Y COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES ANTAGONISTAS DE NPY. LOS ANTAGONISTAS DE NPY SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES / TRASTORNOS INDUCIDOS POR NPY, INCLUYENDO LA OBESIDAD.
PA84937A 1999-04-30 2000-04-12 Compuestos para tratar la obesidad PA8493701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13202999P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
PA8493701A1 true PA8493701A1 (es) 2002-07-30

Family

ID=22452122

Family Applications (1)

Application Number Title Priority Date Filing Date
PA84937A PA8493701A1 (es) 1999-04-30 2000-04-12 Compuestos para tratar la obesidad

Country Status (12)

Country Link
US (2) US6355635B1 (es)
AR (1) AR028824A1 (es)
AU (1) AU2935200A (es)
CO (1) CO5170414A1 (es)
GT (1) GT200000057A (es)
HN (1) HN2000000041A (es)
MA (1) MA26730A1 (es)
PA (1) PA8493701A1 (es)
PE (1) PE20010118A1 (es)
TN (1) TNSN00092A1 (es)
UY (1) UY26130A1 (es)
WO (1) WO2000066578A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK8452002A3 (en) * 1999-12-16 2002-11-06 Schering Corp Substituted 4-(phenyl or pyridyl)imidazole derivatives, pharmaceutical composition comprising the same and use thereof
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
CA2469790A1 (en) * 2001-12-17 2003-06-26 Merck & Co., Inc. Method for treating circadian rhythm disruptions
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
EP1556373A1 (en) * 2002-10-18 2005-07-27 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
DK1651615T3 (da) 2003-07-29 2010-05-25 High Point Pharmaceuticals Llc Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
BRPI0414804A (pt) * 2003-09-26 2006-11-14 Pfizer Prod Inc tratamento de perturbações neurológicas relacionadas com perturbações de sono para movimentos oculares rápidos (rem) com antagonistas dos receptores npy y5
MXPA06003380A (es) * 2003-09-26 2006-06-08 Pfizer Prod Inc Uso de antagonista del receptor npy y5 para el tratamiento de trastornos del ritmo circadiano.
DE102004003812A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Arylsubstituierte Heterozyklen, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US20050256124A1 (en) * 2004-04-15 2005-11-17 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
JP4958785B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
CA2580855A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
US20080064632A1 (en) * 2004-09-24 2008-03-13 Amatruda John M Combination Therapy for the Treatment of Obesity
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2007130075A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CA2614116A1 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
CA2634442A1 (en) * 2005-12-22 2007-07-05 Icagen, Inc. Calcium channel antagonists
US8318927B2 (en) 2006-05-23 2012-11-27 High Point Pharmaceuticals, Llc 6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament
SI2079732T1 (sl) 2006-05-29 2012-03-30 High Point Pharmaceuticals Llc benzodioksol il ciklopropilpiperazin il piridazin njegove soli in solvati in njegova uporaba kot antagonist histaminskega receptorja H
WO2008033575A2 (en) * 2006-09-15 2008-03-20 Metabolon, Inc. Methods of identifying biochemical pathways
DK2125797T3 (da) * 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
US20110060037A1 (en) * 2008-03-12 2011-03-10 David Paul Drucker Woldbye Use of npy y5 receptor antagonists for the prevention of psycho-stimulant and opioid abuse
AU2009322400A1 (en) * 2008-12-03 2011-06-30 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
DK2651915T3 (en) 2010-12-17 2016-07-18 Mitsubishi Tanabe Pharma Corp Continuous arycyclic compound
JP5977349B2 (ja) 2012-06-15 2016-08-24 田辺三菱製薬株式会社 芳香族複素環化合物
US10328064B2 (en) * 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
WO2021099518A1 (en) 2019-11-19 2021-05-27 Modag Gmbh Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440774A (en) 1975-03-03 1984-04-03 Merck & Co., Inc. 3-Amino-2-hydroxypropoxyaryl imidazole derivatives
US4853383A (en) 1975-03-03 1989-08-01 Merck & Co., Inc. β-blocking substituted imidazoles
JPH0251150A (ja) * 1988-08-12 1990-02-21 Konica Corp 新規なシアンカプラーを含有するハロゲン化銀写真感光材料
DE3935514A1 (de) * 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ES2058651T3 (es) * 1990-03-30 1994-11-01 Heumann Pharma Gmbh & Co Uso derivados de guanidina para la fabricacion de un medicamento con actividad antagonista de npy.
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
CZ137297A3 (cs) 1994-11-07 1998-04-15 Pfizer Inc. Substituované benzylaminové deriváty
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
IL133731A0 (en) * 1997-07-03 2001-04-30 Neurogen Corp Certain diarylimidazole derivatives, a new class of npy specific ligands
WO1999048873A1 (en) * 1998-03-25 1999-09-30 Bristol-Myers Squibb Company Imidazolone anorectic agents: i. acyclic derivatives

Also Published As

Publication number Publication date
AR028824A1 (es) 2003-05-28
UY26130A1 (es) 2000-12-29
WO2000066578A1 (en) 2000-11-09
TNSN00092A1 (fr) 2005-11-10
US20010039277A1 (en) 2001-11-08
US6355635B1 (en) 2002-03-12
GT200000057A (es) 2001-10-20
PE20010118A1 (es) 2001-02-03
MA26730A1 (fr) 2004-12-20
HN2000000041A (es) 2001-02-02
US6514966B2 (en) 2003-02-04
CO5170414A1 (es) 2002-06-27
AU2935200A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
PA8493701A1 (es) Compuestos para tratar la obesidad
GEP20074197B (en) 5ht2c receptor modulators
UY28150A1 (es) Agentes terapeuticos
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
UY28144A1 (es) Agentes terapéuticos
UY28752A1 (es) Agentes terapeuticos
UY28374A1 (es) Agentes terapéuticos
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
UY27360A1 (es) Compuestos heterobicíclicos sustituídos con triamida
NO20073776L (no) Trisykliske delta-opioidmodulatorer
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
EA200501868A1 (ru) ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
TW200602330A (en) Compounds and compositions as PPAR modulators
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
PA8542601A1 (es) Bifenilcarboxamidas reductoras de lipidos
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
UY28839A1 (es) Agentes terapeuticos
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización